Results 91 to 100 of about 180,170 (299)

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

Myelomatous Pleural Effusion [PDF]

open access: yes
Multiple myeloma (MM) is a common hematologic malignancy. Pleural effusion is a rare presenting feature of multiple myeloma which carries a poor prognosis.
غیاثی, تقی   +3 more
core  

Biological Treatment Of Multiple Myeloma [PDF]

open access: yes, 2022
This thesis reviews some of the new biological treatments used in multiple myeloma therapy and those currently developed. To understand the use of a drug in disease, the pathophysiology, inner workings and host individuality (e.g., race and age) and ...
Isiramen, Sharon Isimeme
core  

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

open access: yesCell Reports, 2018
Summary: The relationship between promoter proximal transcription factor-associated gene expression and super-enhancer-driven transcriptional programs are not well defined.
Mariateresa Fulciniti   +12 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu   +7 more
wiley   +1 more source

The Danish National Multiple Myeloma Registry [PDF]

open access: yes, 2016
Peter Gimsing,1 Morten O Holmström,2 Tobias Wirenfelt Klausen,3 Niels Frost Andersen,4 Henrik Gregersen,5 Robert Schou Pedersen,6 Torben Plesner,7 Per Trøllund Pedersen,8 Mikael Frederiksen,9 Ulf Frølund,2 Carsten Helleberg,3 Annette ...
Frederiksen M   +13 more
core  

Patients' Experiences With Multiple Myeloma: A Meta-Aggregation of Qualitative Studies. [PDF]

open access: yes, 2017
To access publisher's full text version of this article click on the hyperlink belowTo systematically review qualitative evidence regarding patients' experiences of living with multiple myeloma.
Gunnarsdóttir, Sigríður   +3 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

Targeting the mTOR and TRAIL Pathways in Multiple Myeloma. Resumen de tesis [PDF]

open access: yes, 2012
Extracto de tesis.[ES] Aunque hay varios estudios que destacan la activación de la vía PI3K/Akt en mieloma, hay menos información sobre el estado y el papel de la vía mTOR.
Chen, Xi
core  

Home - About - Disclaimer - Privacy